Drug intelligence / Profile preview

VMD-3866

Development stage: Phase 2
Lead developer: VM Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

VMD-3866 is a topical gel developed by VM Therapeutics for the treatment of pain caused by chemotherapy-induced peripheral neuropathy (CIPN). It is a new molecular entity classified as an analgesic and functions as a calcium channel antagonist, specifically by blocking certain calcium channels in cutaneous nerve fibers, with the aim of reducing nerve activity and neuropathic pain. The drug is being investigated to address the limited efficacy of current therapies for CIPN, and is intended to be applied topically as a gel[1][4][7].

Other names: VMD 3866VMD3866VMD-3866

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on VMD-3866.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VMD-3866.

Explore the full profile